By Marie Rosenthal, MS
The CDC’s Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV, Shingrix, GlaxoSmithKline) to prevent herpes zoster and its related complications, most notably postherpetic neuralgia (PHN), in immunocompetent adults 50 years and older. (MMWR Morbid Mortal Wkly Rep 2018;67[3]:103-108).
The ACIP said that RZV was preferred over the live-attenuated zoster vaccine (ZVL; Zostavax, Merck) and that RZV can be given to adults who